Efficacy Analysis for Molecular Subgroups in MARQUEE: a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib versus Placebo plus Erlo…
J von Pawel, G Scagliotti, S Novello, R Ramlau, A Favaretto, F Barlesi, W Akerley, S Orlov, A Santoro, F Shepherd, D Spigel, V Hirsh, L Sequist, D Shuster, H Zahir, Q Wang, B Schwartz, R von Roemeling, AB Sandler · Pneumologie · 2014 · Heft 02
Bibliografische Angaben
Zusammenfassung
Background: MARQUEE, a Phase 3 study investigating the role of tivantinib (T), a c-MET inhibitor, in prev. treated non-squamous NSCLC, collected EGFR/KRAS genotype on > 90% of random. pats, MET expr. was determined for 42%. In the ITT population, add. of tivantinib to erlotinib (E) signif. improved PFS and ORR but did not show benefit in OS. Add. efficacy analyses in the pre-defined molecular subgroups are presented. Methods: Pats. with stage IIIb/IV non-squamous NSCLC prev. treated with 1 or 2 systemic therapies, incl. a platinum-doublet, were stratified by # of prior therapies, sex, smoking, and EGFR/KRAS muta…
